Binimetinib Tablets (15 mg) are a targeted therapy designed for the treatment of advanced or metastatic melanoma with a BRAF V600E or V600K mutation, often in combination with BRAF inhibitors like dabrafenib. Binimetinib works by inhibiting MEK1/2, key components in the MAPK signaling pathway, which is crucial for tumor cell proliferation and survival. The drug is also indicated for the treatment of non-small cell lung cancer (NSCLC) with the same mutation.

Administered orally, Binimetinib is typically prescribed in doses of 45 mg twice daily for adults, and treatment should be closely monitored for side effects, particularly hepatic toxicity and gastrointestinal issues. Regular monitoring of liver function is recommended during therapy.